TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03950128

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Skills Training (MBST)
Description: This intervention teaches students mindfulness-based skills to help manage their emotions when resolving conflict with their partners. The skills followed the ABCDE acronym. ABCDE stands for awareness, breathing, checking in with your feelings and thoughts, describing your experience, and expressing what you want to change. Students learned about the skills and had opportunities to practice them as well.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducational
Description: This intervention is based on the Love is Not Abuse (LINA) Curriculum (Liz Claiborne Education Development Center (n.d.)). It was adapted to be given over the course of three 50-minute sessions. The selected materials covered (a) what dating abuse is, (b) the pattern of abuse and, (c) technology and dating abuse. The curriculum is interactive and includes handouts, activities, and discussion.
Study: NCT03001921

Intervention type: OTHER
Intervention: No intervention
Description: Registration of all HD patients in the First Affiliated Hospital of Sun Yat-sen University and other hospital which have signed the contract in China.
Study: NCT01054703

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ethmoid Sinus Spacer
Description: Ethmoid Sinus Spacer and Access System used for the local delivery of Kenalog-40
Study: NCT02431858

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: E-Catheter (Pajunk)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sonolong Catheter (Pajunk)
Study: NCT02340234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lebrikizumab
Description: Lebrikizumab will be administered SC as per the schedule specified in the respective arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lebrikizumab
Description: Lebrikizumab will be administered SC as per the schedule specified in the respective arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lebrikizumab
Description: Lebrikizumab will be administered SC as per the schedule specified in the respective arms.
Study: NCT02813291

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tDCS
Description: All subjects will mentally repeat a complex finger sequence with the left hand, for 13 min:~- Subjects of the Sham groups (Young Sham and Elderly Sham) will receive in parallel a sham tDCS of the primary motor cortex.
Study: NCT02340234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching to lebrikizumab will be administered as per the schedule specified in the respective arms.
Study: NCT04475874

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: supervised stretching exercises
Description: 30 to 45-minute supervised active stretching program by a trained physical therapist, three times a week for four weeks starting with a warmup of 5 minutes on a stationary bicycle, half jumping jacks and torso rotations

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: non-supervised active stretching home program
Description: non supervised 30 to 45-minute supervised active stretching program three times a week for four weeks starting with a warmup of 5 minutes on a stationary bicycle, half jumping jacks and torso rotations
Study: NCT00889824

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: balance prosthesis
Description: vibrotactile stimulation
Study: NCT01669772

Intervention type: DRUG
Group type: OTHER
Intervention: DA-9701 and placebo
Description: Prescribe 30mg of DA-9701(motilitone) t.i.d for 1 week and then crossover to placebo.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo and DA-9701
Description: Administer placebo 1 tablet t.i.d for 1 week. After 1 week of washout, crossover to 30mg of DA-9701 t.i.d. for 1 week.
Study: NCT02363621

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab 0.3 mg
Description: Ranibizumab 0.3 mg Patient will receive intravitreal injection of Ranibizumab 0.3 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept 2.0 mg
Description: Patient will receive intravitreal injection of Aflibercept 2.0 mg
Study: NCT02110667

Intervention type: DEVICE
Intervention: Transperineal Ultrasound
Study: NCT02061514

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: maintenance with desflurane
Description: in patients allocated to the desflurane group, general anesthesia will be maintained with desflurane

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: maintenance with propofol
Description: in patients allocated to the propofol group, general anesthesia will be maintained with propofol
Study: NCT02199925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gammaplex 5%
Study: NCT03357536

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Human biological samples
Description: * Blood sample~* Skin biopsy~* Saliva

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Human biological samples
Description: * Blood sample~* Skin biopsy~* Saliva
Study: NCT00645021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-945,598
Description: Administration of CP-945,598 in subjects with mild hepatic function

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-945,598
Description: Administration of CP-945,598 in subjects with moderate hepatic function

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-945,598
Description: Administration of CP-945,598 in subjects with normal hepatic function
Study: NCT04236752

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Ablative Body Radiation (SBRT)
Study: NCT02901418

Intervention type: BIOLOGICAL
Intervention: 200 IU HBIG
Description: additional 200 IU HBIG within 24 hours was used for the experimental group of newborns
Study: NCT05726006

Intervention type: OTHER
Intervention: No Intervention in This study
Description: No Intervention in This study
Study: NCT03770221

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CATCH
Description: Brief, intensive case management service.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CATCH
Description: Brief, intensive case management service.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Financial Incentive
Description: Financial incentive for maintaining contact with CATCH service providers.
Study: NCT02586948

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: extracorporeal CO2 removal (Hemolung device)
Description: ECCO2R in severe exacerbation of COPD patients, requiring invasive mechanical ventilation with persistent respiratory acidosis and dynamic hyperinflation
Study: NCT02312050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GCS-100
Description: 1 mg, 3 mg, or 9 mg IV push injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GCS-100
Description: 1 mg, 3 mg, or 9 mg IV push injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GCS-100
Description: 1 mg, 3 mg, or 9 mg IV push injections

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04368715

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser-assisted frenectomy with 2780 nm Er:Cr;YSGG and 940 nm diode laser

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser-assisted frenectomy with 2780 nm Er:Cr;YSGG and 940 nm diode laser
Study: NCT02196155

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin A
Description: Researchers discovered in the 1950s that injecting overactive muscles with minute quantities of botulinum toxin type-A would result in decreased muscle activity. Botulinum toxin type-A has this effect because it prevents the vesicle where the acetylcholine is stored from binding to the membrane where the neurotransmitter can be released. Botulinum toxin type-A thus blocks the release of acetylcholine by the neuron. This will effectively weaken the muscle for a period of three to four months.~In addition to its cosmetic applications, Botox is currently used in the treatment of spasms and dystonias, by weakening involved muscles, for the 60-70 day effective period of the drug. The main conditions treated with botulinum toxin are: Cervical dystonia (spasmodic torticollis) (a neuromuscular disorder involving the head and neck), Blepharospasm (excessive blinking) etc..

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cortisone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Study: NCT04425252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brequinar
Description: DHODH inhibitor, 100 mg daily x 5 days

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Standard of Care per institutional guidelines for COVID-19 patients
Study: NCT03572348

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transecting anastomotic repair (tAR)
Description: Classic technique, which involves full thickness transection of the corpus spongiosum and the embedded urethral blood supply.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vessel-sparing anastomotic repair (vsAR)
Description: Alternative technique, leaving the bulbar arteries intact, only transecting and excising the narrow segment of the urethra and the surrounding spongiofibrosis.
Study: NCT02382185

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluid optimisation
Description: The intervention will consist of optimising stroke volume with 250ml of Hartmanns solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optimisation of blood pressure
Description: Phenylephrine infusion will be used to target a mean arterial blood pressure to within 30% of baseline (preoperative) value

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Application of clearsight monitor
Description: The clear sight monitor will be applied to measure stroke volume.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Application of clearsight monitor
Description: The clear sight monitor will be applied to measure stroke volume.
Study: NCT01219751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Sunitinib 50 mg D1-D28 every 6 weeks
Study: NCT03054194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2730
Description: capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2730
Description: capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2730
Description: capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: capsules
Study: NCT04122820

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Diagnostic of specific learning disabilities or of Developmental Coordination Disorder
Description: Speech therapy assessment, or occupational therapy. In case of pathological disorder, search for a sensory disorder, and therapeutic management. If the pathological disorder persists for more than six months, elimination of a secondary etiology.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Diagnostic of specific learning disabilities or of Developmental Coordination Disorder
Description: Speech therapy assessment, or occupational therapy. In case of pathological disorder, search for a sensory disorder, and therapeutic management. If the pathological disorder persists for more than six months, elimination of a secondary etiology.
Study: NCT00409006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 milligrams per meter squared (mg/m2), administered by intravenous (IV) infusion every 21 days for 4 cycles (1-4) or 500 mg/m2, IV, every 21 days until disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 milligrams per meter squared (mg/m2), administered by intravenous (IV) infusion every 21 days for 4 cycles (1-4) or 500 mg/m2, IV, every 21 days until disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75 mg/m2, IV, every 21 days for 4 cycles (1-4) or 75 mg/m2, IV, every 21 days for 4 cycles with optional continuation for 2 additional cycles until disease progression or unacceptable toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75 mg/m2, IV, every 21 days for 4 cycles (1-4) or 75 mg/m2, IV, every 21 days for 4 cycles with optional continuation for 2 additional cycles until disease progression or unacceptable toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: 250 mg, administered orally once daily beginning at Cycle 5 until disease progression or unacceptable toxicity
Study: NCT03694210

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EndoRotor Therapy
Description: To evaluate the EndoRotor's ability to safely remove non-viable/necrotic tissue for direct endoscopic necrosectomy in patients with walled off pancreatic necrosis.
Study: NCT00628706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delta9-tetrahydrocannabinol (THC)
Description: inhalation of 6 mg liquid THC, vaporized by means of a Volcano vaporizer

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Delta9-tetrahydrocannabinol (THC)
Description: inhalation of 6 mg liquid THC, vaporized by means of a Volcano vaporizer
Study: NCT04025762

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hybrid closed-loop system (CamAPS FX)
Description: Hybrid closed-loop system

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sensor augmented pump therapy
Description: Sensor augmented pump therapy
Study: NCT04223323

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Almonds
Description: Participants in the intervention group will consume 2oz of almonds daily over the course of 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Pretzels
Description: Participants in the control group will consume an isocaloric amount of pretzels daily over the course of 12 weeks.
Study: NCT00484198

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: 45 mg over-encapsulated tablet administered orally, once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Rivoglitazone-matching placebo administered as a tablet orally, once daily or a pioglitazone-matching placebo administered as an over-encapsulated tablet orally, once daily capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivoglitazone
Description: 1.0 mg tablet administered orally, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivoglitazone
Description: 1.5 mg tablet administered orally, once daily
Study: NCT03241121

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time restricted feeding
Description: To eat only during a self-selected window of 12 hours, with no advice on nutrition quality, quantity or caloric intake

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Regular dietary advices
Description: Regular dietary advices by a trained dietitian or research nurse according to current nutrition guidelines

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Eating patterns
Description: Data collection on eating patterns via the smartphone app

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eating patterns
Description: Data collection on eating patterns via the smartphone app
Study: NCT02889172

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem Solving Therapy
Description: It will be apply a Brief Intervention (PST) for patients with Type II Diabetes Mellitus and Obesity who receive treatment in primary care centers from Mexico City to evaluate if PST improvement the depressive and anxiety symptoms and help to adhere to treatment and stabilize their metabolic variables
Study: NCT02837185

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin injection
Description: Botulinum toxin injection for cervical dystonia subjects (as part of clinical care)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiological measures
Description: These include TMS and EMG measurements

Intervention type: OTHER
Group type: OTHER
Intervention: Physiological measures
Description: These include TMS and EMG measurements
Study: NCT04047628

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: 1. PBSC mobilization \& collection regimen per protocol/ institutional standards includes: intravenous cyclophosphamide (Cytoxan®), 4 grams/m\^2); intravenous mesna (Mesnex®),a total delivery of 4 grams/m\^2); oral dexamethasone, 10 mg dose, four times daily); subcutaneous filgrastim,10 mcg/kg/day until leukapheresis goal is completed; and CD34+ peripheral blood stem cells collection by leukapheresis.~2. Conditioning per protocol\& institutional standards:~   * 6-day BEAM (e.g. Carmustine (BCNU), Etoposide (VP-16), Cytarbine (Ara-C), and Melphalan) chemotherapy protocol and,~  * rabbit anti-thymocyte globulin (rATG) 2.5 mg/kg/day x2~3. Autologous cryopreserved graft infusion: The target Cluster of Differentiation (CD)34+ cell dose for infusion is 5 x 10\^6 CD34+ cells/kg (minimum 4 x 10\^6 CD34+ cells/kg; maximum 7.5 x 10\^6 CD34+ cells/kg).~For 1\&2 above: Ideal body weight (IBW) versus Actual Body Weight (ABW) are applicable.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Best Available Therapy (BAT)
Description: Disease-modifying therapy (DMT) selected by the Site Investigator from the below:~* cladribine~* natalizumab~* alemtuzumab~* ocrelizumab,~* rituximab,~* ofatumumab, or~* ublituximab
Study: NCT01038167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telaprevir
Description: Tablet, Oral, 750mg, every 8 hours, Day 1-11 of Period 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telaprevir
Description: Tablet, Oral, 750mg, every 8 hours, Day 1-13 of Period 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Solution, Oral, 100mg, Day 1 of Period 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Solution, Oral, 10mg, Day 1 and Day 8 of Period 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: Capsule, Oral, 2mg, Day 1 of Period 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: Capsule, Oral, 0.5mg, Day 8 of Period 2
Study: NCT01449006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: Maraviroc oral tablet. Dosage: 150 mg twice daily, 300 mg twice daily, or 600 mg twice daily. Dosing will be dependent on the participant's background HAART therapy, and will be in accordance with the product information sheet.
Study: NCT02761343

Intervention type: OTHER
Group type: OTHER
Intervention: MRI scan
Description: Following the clinically indicated cardiac ablation procedure, a post ablation MRI scan will be performed.
Study: NCT00380731

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Cognitive Behavioral Therapy
Description: CBT includes 16 weekly 60-minute individual CBT sessions for social anxiety disorder.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Cognitive Behavioral Therapy
Description: CBT includes 16 weekly 60-minute individual CBT sessions for social anxiety disorder.
Study: NCT03350815

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 150 mg open-label secukinumab
Description: All patients in Treatment Period 1 received 150 mg s.c. injection open-label secukinumab.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 150 mg open-label secukinumab
Description: All patients in Treatment Period 1 received 150 mg s.c. injection open-label secukinumab.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 150 mg open-label secukinumab
Description: All patients in Treatment Period 1 received 150 mg s.c. injection open-label secukinumab.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 150 mg double-blinded secukinumab
Description: Treatment Period 2 Patients who achieved responder status entered Treatment Period 2 and continued to receive 150 mg s.c. (1 s.c. injection of secukinumab 150 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 150 mg double-blinded secukinumab
Description: Treatment Period 2 Patients who achieved responder status entered Treatment Period 2 and continued to receive 150 mg s.c. (1 s.c. injection of secukinumab 150 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 300 mg double-blinded secukinumab
Description: Treatment Period 2 300 mg (2 s.c. injections of the 150 mg dose)
Study: NCT04305366

Intervention type: OTHER
Intervention: Tissue collection
Description: Blood draw, Fine Needle Aspiration, Saliva Swab, Tumor/tissue sample
Study: NCT05355662

Intervention type: OTHER
Intervention: Age
Description: The study was retrospective and did not involve the application of interventions.

Intervention type: OTHER
Intervention: Age
Description: The study was retrospective and did not involve the application of interventions.

Intervention type: OTHER
Intervention: Age
Description: The study was retrospective and did not involve the application of interventions.
Study: NCT03818191

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acamprosate
Description: The research pharmacy contracted for this study will randomize the study participants for all sites with placebo or acamprosate.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The research pharmacy contracted for this study will randomize the study participants for all sites with placebo or acamprosate.
Study: NCT03274544

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PROLUNG
Description: Chinese herbal medicine formula PROLUNG with individual herbs of the formula are listed as follows (weight in granule preparation):~* Huang Qi (Radix Astragali Membranaceus): 2 g~* Dan Shen (Radix Salviae Miltiorrhizae): 1 g~* Jiang Huang (Rhizoma Curcumae Longae): 1 g~* Yin Xing (Semen Gingko Bilobae): 1 g~* Mai Men Dong (Tuber Ophiopogonis Japonoci): 1 g~* Bai He (Bulbus Lilii): 1g~* Jin Yin Hua (Flos Lonicerae Japonicae): 1 g~* Zi Su Ye (Folium Perillae Frutescentis): 1 g~* Yin Yang Huo (Herba Epimedii): 1g
Study: NCT01181817

Intervention type: OTHER
Group type: OTHER
Intervention: fMRI and MRS
Description: fMRI and MRS
Study: NCT00966615

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: double-chamber bag Stay-Safe Balance system
Description: 2-L exchange; three times a day

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: glucose-based dialysis solution
Description: 2-L exchange; three times a day